Building on these findings and our preliminary work, we aimed to determine whether the combined use of deep learning algorithms and physio-metabolic MRI data enables a reliable preoperative classification of the IDH gene mutation status of glioma patients in a clinical setting. This evidence concerns the gene IDH2 and glioma.